Form 8-K BIOSPECIFICS TECHNOLOGIE For: Dec 22

Go back to Form 8-K BIOSPECIFICS TECHNOLOGIE For: Dec 22

Biospecifics (BSTC) Receives Positive CHMP Opinion for XIAPEX; Aegis Capital Comments

December 23, 2014 12:32 PM EST

Aegis Capital offered commentary on Biospecifics Technologies (NASDAQ: BSTC) following news that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of XIAPEX for the treatment of adult men with Peyronie's disease with a palpable plaque and a curvature deformity of at least 30 degrees at the start of therapy.

Analyst Yi Chen commented, BioSpecifics Technologies announced yesterday... More